Actively Recruiting
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Led by GlaxoSmithKline · Updated on 2026-01-07
84
Participants Needed
6
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
CONDITIONS
Official Title
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status of 0 or 1 with no decline in 2 weeks before first dose
- Adequate organ function
- Histologically confirmed unresectable adenocarcinoma of the colon or rectum (Cohort A)
- Histologically or cytologically confirmed adenocarcinoma of the prostate (Cohort B)
You will not qualify if you...
- Malignancy other than study disease progressing or needing treatment in past 24 months except certain skin or in-situ carcinomas fully removed
- Major surgery within 28 days before first dose
- Significant bleeding symptoms or tendency within 1 month before first dose
- Serious infection within 4 weeks before first dose
- Untreated or progressing brain or CNS metastases
- Current or prior interstitial lung disease or pneumonitis requiring high-dose steroids
- Autoimmune disease needing systemic treatment in 2 years before screening
- Use of immunosuppressive agents within 30 days before first dose except low-dose corticosteroids (prednisone 610 mg/day or equivalent)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
GSK Investigational Site
Lake Success, New York, United States, 11042
Actively Recruiting
2
GSK Investigational Site
Tugun, Queensland, Australia, 4224
Actively Recruiting
3
GSK Investigational Site
Barcelona, Spain, 08035
Actively Recruiting
4
GSK Investigational Site
Madrid, Spain, 28034
Actively Recruiting
5
GSK Investigational Site
Madrid, Spain, 28050
Actively Recruiting
6
GSK Investigational Site
Málaga, Spain, 29010
Actively Recruiting
Research Team
U
US GSK Clinical Trials Call Center
CONTACT
E
EU GSK Clinical Trials Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here